Mesoblast Limited (NASDAQ:MESO – Get Free Report) was the target of a significant decline in short interest during the month of July. As of July 15th, there was short interest totalling 373,300 shares, a decline of 18.9% from the June 30th total of 460,500 shares. Based on an average daily trading volume, of 219,200 shares, the short-interest ratio is presently 1.7 days.
Institutional Investors Weigh In On Mesoblast
A number of institutional investors and hedge funds have recently modified their holdings of MESO. Chase Investment Counsel Corp acquired a new stake in shares of Mesoblast during the first quarter worth $298,000. GAMMA Investing LLC raised its holdings in Mesoblast by 50.1% during the 2nd quarter. GAMMA Investing LLC now owns 4,981 shares of the company’s stock worth $34,000 after buying an additional 1,663 shares during the period. Perkins Coie Trust Co purchased a new stake in Mesoblast during the second quarter valued at about $68,000. Finally, Chapin Davis Inc. boosted its holdings in shares of Mesoblast by 50.0% in the second quarter. Chapin Davis Inc. now owns 15,000 shares of the company’s stock worth $102,000 after buying an additional 5,000 shares during the period. Institutional investors and hedge funds own 1.43% of the company’s stock.
Mesoblast Stock Performance
NASDAQ MESO traded down $0.02 on Friday, reaching $7.40. The company’s stock had a trading volume of 89,252 shares, compared to its average volume of 216,542. The stock has a market cap of $844.92 million, a PE ratio of -6.61 and a beta of 3.48. Mesoblast has a twelve month low of $1.61 and a twelve month high of $8.66. The firm’s 50 day moving average is $7.41 and its two-hundred day moving average is $5.07.
Analyst Upgrades and Downgrades
View Our Latest Report on Mesoblast
Mesoblast Company Profile
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Recommended Stories
- Five stocks we like better than Mesoblast
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Is Crypto Cool Again? What Stocks You Should Be Watching
- What are earnings reports?
- Why Call Options Volume for These 2 Stocks Spiked Together
- What is Forex and How Does it Work?
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.